Here's Why I Still Wouldn't Touch Energy Transfer LP -- Even With That 6.9% Yield
A ~7% yield isn't a bonus -- it signals concerns around execution risk, capital intensity, and long-…

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
1 signal unavailable — limited data for this stock
Trend
+14.5% vs SMA 50 · +34.9% vs SMA 200
Momentum
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $3.2B $3.2B–$3.3B | — | $27.48 | — | ±4% | High11 |
FY2026(current) | $3.3B $3.2B–$3.4B | ▲ +2.5% | $29.37 | ▲ +6.9% | ±8% | High12 |
FY2027 | $3.8B $3.3B–$4.4B | ▲ +14.4% | $33.96 | ▲ +15.6% | ±23% | High11 |
A ~7% yield isn't a bonus -- it signals concerns around execution risk, capital intensity, and long-…

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians